Stockreport

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

MBX Biosciences, Inc.  (MBX) 
PDF Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 141 [Read more]